ASH 2022 | CCTG LY.17 trial: R-GDP versus R-DICEP salvage therapy in patients with R/R DLBCL
John Kuruvilla, MD, FRCPC, Princess Margaret Cancer Centre, Toronto, Canada, shares some insights into the randomized Phase II Canadian Cancer Trials Group (CCTG) LY.17 study, which is evaluating novel salvage therapy pre-autologous stem cell transplantation (autoSCT) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Patients in this trial were randomized to receive either rituximab combined with gemcitabine, dexamethasone and cisplatin (R‐GDP), or rituximab plus dose-intensified cyclophosphamide, etoposide and cisplatin (R-DICEP). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Gilead: Consultancy, Honoraria; Bristol Myers Squibb: Consultancy, Honoraria; Karyopharm: Consultancy, Honoraria, Other: DSMB; Merck: Consultancy, Honoraria, Research Funding; Abbvie: Consultancy, Honoraria; Medison Ventures: Consultancy; Antengene: Consultancy; Novartis: Honoraria; Janssen: Honoraria; Amgen: Honoraria; Astra Zeneca: Honoraria, Research Funding; Roche: Consultancy, Honoraria, Research Funding; Inctye: Honoraria; Seattle Genetics: Consultancy, Honoraria; Pfizer: Honoraria; Lymphoma Canada: Membership on an entity’s Board of Directors or advisory committees.
